In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Jackie Chan, 70, Tells Fans 'Don't Worry' About Photos of Him Looking Older: 'It's Just a Character' Will Smith Thanks Jackie Chan for His 'Eternal Impact' on Smith Family in Heartfelt 70th ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amgen (AMGN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.